• SOURCE: S&D Group at European Parliament

More transparency in clinical trials and more cross-border projects will benefit patients

ID

325345

Description
Edited Package
Shotlist
BUDAPEST, HUNGARY (DATE UNKNOWN) (EUROEPAN PARLIAMENT AUDIOVIDUAL - ACCESS ALL) 1. CUTAWAY: VARIOUS OF THE PRODUCTION OF PHARMACEUTICAL PRODUCTS IN BUDAPEST BRUSSELS, BELGIUM (APRIL 02, 2014) (SOCIALISTS AND DEMOCRATS, EUROPEAN PARLIAMENT - ACCESS ALL) 1. CUTAWAY: VARIOUS OF EUROPEAN PARLIAMENT IN BRUSSELS (EXTERIOR) 2. CUTAWAYS: VARIOUS OF THE VOTE ON CLINICAL TRIALS 3. CUTAWAY: GLENIS WILMOTT TALKING TO HER ASSISTANT 4. GLENIS WILMOTT (S&D MEP, UK) SAYING (ENGLISH): "Well at the moment there is only half of the trials that are published, it is really important to have to the results of all trials publishes. That makes for good science and it means that patient benefit is better for patient safety and it also allows for public trust in medicine." 5. CUTAWAY: GLENIS WILMOTT TALKING TO HER ASSISTANT 6. GLENIS WILMOTT (S&D MEP, UK) SAYING (ENGLISH): "All trials will have to be published. Clinical studies report will have to be uploaded, whether the trials were positive or negative. And that is really important because it means that people can look at that information and see whether the trials have been successful or not." 7. CUTAWAY: GLENIS WILMOTT TALKING TO HER ASSISTANT 8. GLENIS WILMOTT (S&D MEP, UK) SAYING (ENGLISH): "This is about making sure that we have new and better medicines available to patients. At the end of the day, that is what matters the most in this regulation." 9. CUTAWAY: VARIOUS OF THE FAMHP (EXTERIOR) 10. CUTAWAY: VARIOUS OF GREET MUSCH WRITING AT HER DESK 11. GREET MUSCH (GENERAL DIRECTOR, FAMHP) SAYING (ENGLISH): "This is crucial for the patient if we want to empower the him in the decision making process. I think it is an important base of information that can be offered to the patient. " 12. CUTAWAY: VARIOUS OF GREET MUSCH WRITING AT HER DESK 13. GREET MUSCH (GENERAL DIRECTOR, FAMHP) SAYING (ENGLISH): "It is clear that not all the results of all clinical trials are published today. For the protection of the patient, there have been measures foreseen. It will be asked to the Member States to foreseen penalties in case they do not publish to requested data or in case of safety issue. So I think it is really to protect the patient that Member States are asked to foreseen these penalties. " 14. CUTAWAY: VARIOUS OF GREET MUSCH WRITING AT HER DESK
Usage Rights/Restrictions
This media asset is free for editorial broadcast, print, online and radio use. It is restricted for use for other purposes.

Contact

  • Client Relations
    TheNewsMarket